Clinical Trial Update: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is investigating peginterferon alfa-2a in chronic hepatitis B patients at high risk of hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: Shanghai Nanhui Nanhua Hospital | Conditions: Hepatitis B | Phase 4 | Status: UNKNOWN